Venous thromboembolism (VTE) is a common adverse event following surgery, with risks related to the nature of the surgery, the presence of cancer, and other comorbidities. In a randomized, double-blind,… Click to show full abstract
Venous thromboembolism (VTE) is a common adverse event following surgery, with risks related to the nature of the surgery, the presence of cancer, and other comorbidities. In a randomized, double-blind, placebo-controlled trial with patients having laparoscopic surgery for colorectal cancer, Becattini et al demonstrated that the addition of 3 weeks of rivaroxaban to 1 week of low molecular weight heparin reduces the relative risk of VTE by 73% without increasing the bleeding risk. This finding establishes a new standard of prophylaxis for this surgical scenario.
               
Click one of the above tabs to view related content.